Diligence memo · auto-generated · as of July 2, 2026
PharmaCann Inc.
PharmaCann Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
PharmaCann Inc. operates in Biotech / Pharma, based in CHICAGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
PharmaCann Inc. has raised $509M in disclosed capital across 19 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $110M on 2021-06-14.
Most recent recorded round closed around 2024-03-28.
Valuation (modeled)modeled
Provath models PharmaCann Inc. at approximately $413M (range $163M–$592M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.21× the median modeled value of Series D+ Biotech / Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round stepped up 3.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Alto Pharmacy Holdings, Inc., Colossal Biosciences Inc., Vedanta Biosciences, Inc., Seismic Therapeutic, Inc., Vignette Bio, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.